跳转到文章内容

Key takeaways

  • Equity performance across the average stock this year has been muted and the economy has begun to slow, setting up the key question for 2024: will we experience a soft landing or a more material decline in corporate profits?
  • Small- and mid-cap stock participation has been missing in the narrow market rally. We will continue to watch breadth indicators, looking for material expansion to suggest a healthier outlook, but without improvement we will remain cautious.
  • We expect market leadership to broaden in 2024 and believe high-quality defensive stocks, particularly in health care, will hold up better than the current mega cap leaders in an economic downturn.

Mega cap rally not an all clear sign for equities

Coming into the year we anticipated the Federal Reserve’s rapid withdrawal of liquidity would keep pressure on equities and ultimately lead to a recession. While the S&P 500 Index briefly entered correction territory in late October, equity markets surged in November as a massive rally in interest rates pushed down yields amid disinflationary trends and the expectation that not only had the Fed finished its rate hikes, but rate cuts would also begin sooner than previously expected. While on the surface this sounds like an attractive backdrop for investors, and inflationary pressures are indeed abating, we are not yet ready to declare the “all clear” signal for equities. In fact, despite gains in the large cap-dominated indexes, equity performance across the average stock has been muted and the economy is now starting to show more significant signs of slowing. The question for 2024 is whether the economy will experience a soft landing as consensus now expects, or a more material decline in corporate profits.

We continue to forecast at least a mild recession, as many of the key indicators we track still point in that direction. The Conference Board’s basket of leading economic indicators (LEI) has declined sharply over the last two years and remains disconnected with gross domestic product (GDP) growth. We would remind investors that the GDP impact of negative LEIs lags, which makes forecast timing difficult. In addition, the yield curve has been inverted for over a year, a duration consistent with where economic weakness should begin to become more evident.

While we believe investors remain too complacent regarding corporate profits and the economy, our prior forecasts underestimated the impact of fiscal stimulus on the US financial system during the COVID years. Huge fiscal spending programs materially boosted GDP this past year and their impact continues to help counteract the effects of tighter monetary conditions. In addition, structural changes in employment have made corporations reluctant to cut employees, keeping labor markets tight. As a result, consumption, which accounts for two-thirds of US GDP, remains at higher levels than might be expected during more traditional tightening cycles. That said, consumer savings are now back at pre-COVID levels, the housing market is both slow and unaffordable and employment is likely to deteriorate as employers attempt to maintain margins in the face of slowing demand. Although a recession remains our base case, we believe that the odds of a significant economic downturn are lower as the lingering effects of fiscal spending are helping cushion the impact of monetary tightening.

In addition to trying to read the economic tea leaves, we believe that market breadth provides valuable insights about the durability of future market performance. While this year’s market return has been better than we expected, its underlying performance is far more varied and nuanced than one might assume by just looking at the S&P 500. Year-to-date returns have been disproportionately driven by the top seven weightings of the S&P 500, which have accounted for approximately 70% of the overall index return (as of November) and earned the nickname the Magnificent Seven. As a result, large cap growth strategies have surged this past year. In contrast, all value styles, as well as all small cap categories, have trailed those stocks by approximately 30 percentage points.

Historically, at the start of a new bull market, small and mid cap stocks often lead the way in terms of performance, and participation is robust across the spectrum. In the current narrow market, small and mid cap stock participation has been a missing component to the rally. Furthermore, only three of 11 sectors in the S&P 500 are outperforming the overall index, a condition that has impacted the returns for most diversified strategies. We will continue to watch breadth indicators, hoping to see them expand materially as a leading indicator of a healthier outlook, but without improvement we will continue to lean cautious.

Exhibit 1: Equal Weighted Underperformance Signals Active Opportunity

Source: FactSet. Data as of November 30, 2023. Indexes are unmanaged and one cannot directly invest in them. They do not include fees, expenses or sales charges. Past performance is not an indicator or a guarantee of future results.

One consequence of the current narrow market is a historically wide performance differential between the market-cap weighted and equal-weighted S&P 500 (Exhibit 1). Over the course of the next year, we expect this divergence to reverse as other sectors of the market gain relative ground. While we do not expect the Magnificent Seven to decline materially, we also do not anticipate the same step function higher in earnings for those companies as we saw in 2023. Instead, we expect relative leadership to broaden and include more defensive-oriented groups that have been underperformers this past year. We believe high-quality defensive stocks, particularly in health care, will hold up better than the current mega cap leaders in an economic downturn. Finally, we believe banks will be an important group to watch as a potential barometer of economic weakness due to their sensitivity to potential credit issues. We remain open minded however, that this time could be different due to the economic impact and remedies associated with COVID, but we will wait patiently for the data before reaching that conclusion.



Copyright ©2025 富蘭克林鄧普頓。版權所有。

本文件僅供一般參考。本文件不應被視作個人投資建議或買賣或持有任何基金股份或證券的要約或招攬。有關本文所提及的任何證券的資料並不足以用作制定投資決策。投資涉及風險。投資價值可升或跌,過往業績不代表或不保證將來的表現。投資收益是以資產淨值計算,已考慮股息再投資及資本增長或損失。投資收益以所示貨幣計價,該等貨幣可能是美元/港元以外的貨幣(「外幣」)。因此,以美元/港元交易的投資者需承受美元/港元與外幣之間匯率波動的風險。投資者應仔細閱讀銷售文件,以獲取進一步資料,包括風險因素。

本文件所載的數據、評論、意見、預測及其他資料如有更改恕不另行通知。不保證投資產品目標將會實現,亦不保證所示預測將會實現。表現亦可能受貨幣波動影響。流動性下降或會對資產價格產生不利影響。貨幣波動可能會影響海外投資的價值。如果投資產品投資於新興市場,風險可能高於投資於已發展市場。如果投資產品投資於衍生工具,則需承擔特定風險,這可能會增加投資產品承受的風險水平。如果投資產品投資於特定行業或地區,回報的波動程度可能高於更多元化的投資產品投資。富蘭克林鄧普頓不就使用本文件或其所載的任何評論、意見或估計而導致的任何直接或間接後果性損失承擔任何責任。在未得到富蘭克林鄧普頓的事先書面同意下,不得以任何方式複製、派發或發表本文件。

名稱中包含「(已對沖)」的任何股份類別將嘗試對沖本基金基礎貨幣與股份類別計值貨幣之間的貨幣風險,但不保證可以成功對沖。在某些情況下,投資者可能涉及額外風險。

若閣下對其中任何資料有疑問,謹請與閣下的財務顧問聯絡。

只適用於UCITS基金: 此外,投資者權利概要可從這裡獲得。根據 UCITS 指令,基金/子基金被通知在不同地區進行營銷。 基金/子基金可以使用 UCITS 指令第 93a 條中包含的程序隨時終止任何股份類別和/或子基金的此類通知。

只適用於AIFMD基金:此外,投資者權利摘要可從這裡獲得。根據 AIFMD 指令,基金/子基金被通知在不同地區進行營銷。 基金/子基金可以使用 AIFMD指令第 32a 條中包含的程序隨時終止任何股份類別和/或子基金的此類通知。

為避免疑問,如果您決定投資,即代表您將購買本基金的單位/股份,並不是直接投資於本基金的相關資產。

本文件由富蘭克林鄧普頓投資(亞洲)有限公司發行,並未為香港證監會所審閱。

除非另有註明,所有資料截至上述日期。資料來源:富蘭克林鄧普頓。

CFA® 及Chartered Financial Analyst®為特許金融分析師協會擁有的商標。